Form 8-K · Current Report · Filed 2024-07-29
Revvity Reports Q2 2024 Financial Results
Revvity, Inc. reported financial results for the second quarter ended June 30, 2024, showing GAAP revenue of $692 million, a 2% decrease from the same period last year. The company reported GAAP earnings per share (EPS) of $0.45, compared to $0.28 in the same period a year ago. Adjusted EPS from continuing operations was $1.22. Revvity also raised its full-year 2024 adjusted EPS guidance to a range of $4.70-$4.80. The diagnostics segment saw a 1% revenue increase, while the life sciences segment experienced a 7% revenue decrease.
- Filer
- Revvity Inc. RVTY · NYSE
- Filed
- Accession
- 0000031791-24-000018
- CIK
- 0000031791
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$115.15
Next session
+10.4%
Since filing
+27.4%
Latest close
$146.73
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RVTY reporting the same item, with the next session's move:
Exhibits (1)
About Revvity Inc.
Revvity Inc. is a prominent company in the healthcare and biological sciences field, offering a comprehensive suite of solutions aimed at improving global health outcomes. The company's core focus lies in delivering innovative products and services that range from diagnostic tools to advanced analytical capabilities for life sciences research. Revvity serves a wide array of sectors including biotechnology, pharmaceuticals, and clinical diagnostics, providing essential tools and data analytics that aid in disease discovery, drug development, and health monitoring. The company's expertise in deploying cutting-edge technologies further reinforces its position as a critical enabler of scientific research and innovation. With its global reach and commitment to enhancing healthcare delivery, Revvity Inc. plays a pivotal role in advancing the capabilities of medical and scientific communities worldwide, driving progress in critical areas such as personalized medicine and preventive healthcare.
Never miss another RVTY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.